Induction of tumouricidal leucocytes by the intranasal application of MTP-PE, a lipophilic muramyl peptide.
Single intranasal applications of MTP-PE, a lipophilic muramyl peptide, induce tumouricidal and tumouristatic leucocytes in the lungs of rats. In ex vivo assays the tumouristatic activity was detectable for 8 days after drug administration. By separation of the effector cells on Ficoll-Hypaque gradients, it was shown that both neutrophils and macrophages are responsible for this activity. Using the B16/BL6 melanoma system in mice, there was a high survival rate after repeated intranasal applications of MTP-PE.
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives* / Q000276:immunology; D000281:Administration, Intranasal; D000818:Animals; D002478:Cells, Cultured; D005260:Female; D007111:Immunity, Cellular; D007167:Immunotherapy; D007962:Leukocytes / Q000276:immunology*; D008168:Lung / Q000276:immunology; D008264:Macrophages / Q000276:immunology; D051379:Mice; D009374:Neoplasms, Experimental / Q000628:therapy*; D009504:Neutrophils / Q000276:immunology; D010714:Phosphatidylethanolamines / Q000276:immunology; D051381:Rats; D013997:Time Factors
D010714:Phosphatidylethanolamines; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C035104:muramylNAc-Ala-isoGln-Lys-tripeptide